The intervention being tested is BNT327, administered in two dose levels, combined with standard chemotherapy drugs such as etoposide, carboplatin, paclitaxel, and topotecan. The purpose is to ...

The update on this clinical study could influence BioNTech’s stock performance by potentially boosting investor confidence if the results are favorable. The involvement of collaborators like ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.

In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.